WALTHAM, Mass., Oct. 27, 2022 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will report third quarter 2022 financial results and provide a business update on Thursday, November 3. after the end of the US fiscal year. markets.
In connection with the earnings release, Syndax management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, November 3, 2022 to discuss the Company’s financial results and provide a business update.
The live audio webcast and accompanying slides can be accessed via the Events and presentations page in the Investors section of the Company’s website. Alternatively, the conference call can be accessed by the following means:
Conference ID: SYNDAXQ3
National hotline: 800-225-9448
International dial-in number: 203-518-9708
Live webcast: https://www.veracast.com/webcasts/OpenEx/General/S03S7x.cfm
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days after the call.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline highlights include revumenib (SNDX-5613), a highly selective inhibitor of the Menin-MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1), both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Pharmaceuticals, Inc.
SOURCE Syndax Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:SNDX